Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADAM10
REST API REST API
Homo sapiens
ADAM10 is differentially expressed in 349 experiments: 143 organism parts: liver, lung, ... (141 more);, 244 disease states: normal, control, ... (242 more);, 120 cell types 467 cell lines 52 compound treatments and 88 other conditions.
Synonyms kuz, CD156c, HsT18717, MADM
Orthologs adam10a (Danio rerio)   Adam10 (Mus musculus)   Adam10 (Rattus norvegicus)   ENSCING00000009495 (Ciona intestinalis)   adam10b (Danio rerio)   ADA10_BOVIN (Bos taurus)   Q5F3N4_CHICK (Gallus gallus)   kuz (Drosophila melanogaster)   adam10 (Xenopus laevis)   Q56JJ2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term endomembrane system, plasma membrane, protein binding, cytoplasm, metalloendopeptidase activity, epidermal growth factor receptor signaling pathway, Golgi-associated vesicle, positive regulation of cell proliferation, metallopeptidase activity, peptidase activity, SH3 domain binding, Golgi apparatus, membrane protein ectodomain proteolysis, metal ion binding, receptor binding, cell-cell signaling, integrin-mediated signaling pathway, Notch receptor processing, protein kinase binding, nucleus, postsynaptic density, endopeptidase activity, integrin binding, Notch signaling pathway, proteolysis, protein homodimerization activity, integral to membrane, positive regulation of cell growth, cell surface, zinc ion binding, monocyte activation, in utero embryonic development, response to tumor necrosis factor, positive regulation of cell migration, PMA-inducible membrane protein ectodomain proteolysis, positive regulation of T cell chemotaxis, constitutive protein ectodomain proteolysis, negative regulation of cell adhesion, protein phosphorylation
InterPro Term Peptidase_M12B_N, Blood-coag_inhib_Disintegrin, Peptidase_M12B
UniProt Accession B5MC71, A8MY20, C9J994, C9J9B4, O14672, B4DU28
Search EB-eye ENSG00000137845
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (47 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-5823, E-GEOD-20081, E-GEOD-3529
SW480
4
E-MEXP-1014, E-GEOD-18005, E-MTAB-37, E-GEOD-2509
HCC38
2
E-MTAB-37, E-MTAB-62
primary culture
2
E-GEOD-2450, E-GEOD-1657
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MOLT4
2
E-MTAB-62, E-MTAB-37
461 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-2822, E-GEOD-21909, E-GEOD-21750, E-TABM-34, ... (52 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3204, E-GEOD-26672
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
mononuclear
2
E-GEOD-26672, E-GEOD-13987
CXCR4 positive
1
E-GEOD-15893
114 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-12254, E-TABM-15, E-MEXP-2280, ... (79 experiments)

Factor Value U/D Experiments
multiple myeloma
3
E-GEOD-6691, E-MTAB-62, E-GEOD-2113
prostate carcinoma
1
3
E-MEXP-2034, E-MTAB-62, E-GEOD-3868, E-GEOD-7307
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-3185, E-GEOD-16363
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-1880
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
238 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-697, ... (30 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
nocodazole
2
E-GEOD-6431, E-GEOD-571
glutamine
2
E-MEXP-941, E-MEXP-1335
heregulin
1
E-GEOD-6462
filtered air
1
E-TABM-127
sapphyrin PCI-2052
1
E-GEOD-6400
46 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-21374, E-GEOD-4619, E-GEOD-21589, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-MEXP-480, E-GEOD-3325, ... (12 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, E-TABM-868, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-TABM-127, E-GEOD-20504, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-7819, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (9 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

Qrt pcr areg dct
studied in E-GEOD-5851

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.312 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM